ro15 Search Results


flumazenil  (TargetMol)
90
TargetMol flumazenil
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Flumazenil, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flumazenil/product/TargetMol
Average 90 stars, based on 1 article reviews
flumazenil - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
flumazenil  (MedChemExpress)
93
MedChemExpress flumazenil
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Flumazenil, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flumazenil/product/MedChemExpress
Average 93 stars, based on 1 article reviews
flumazenil - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
3h ro15 1788  (Revvity)
91
Revvity 3h ro15 1788
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
3h Ro15 1788, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3h ro15 1788/product/Revvity
Average 91 stars, based on 1 article reviews
3h ro15 1788 - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
ro15  (Tocris)
91
Tocris ro15
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Ro15, supplied by Tocris, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ro15/product/Tocris
Average 91 stars, based on 1 article reviews
ro15 - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
h ro15 4513  (Revvity)
91
Revvity h ro15 4513
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
H Ro15 4513, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/h ro15 4513/product/Revvity
Average 91 stars, based on 1 article reviews
h ro15 4513 - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
hy b1894a cefditoren cdn third approved  (MedChemExpress)
92
MedChemExpress hy b1894a cefditoren cdn third approved
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Hy B1894a Cefditoren Cdn Third Approved, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy b1894a cefditoren cdn third approved/product/MedChemExpress
Average 92 stars, based on 1 article reviews
hy b1894a cefditoren cdn third approved - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier
musechem  (MedChemExpress)
93
MedChemExpress musechem
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Musechem, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/musechem/product/MedChemExpress
Average 93 stars, based on 1 article reviews
musechem - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
methyl-3h]ro15-1788  (NEN Life Science)
90
NEN Life Science methyl-3h]ro15-1788
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Methyl 3h]Ro15 1788, supplied by NEN Life Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/methyl-3h]ro15-1788/product/NEN Life Science
Average 90 stars, based on 1 article reviews
methyl-3h]ro15-1788 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ro 15-4513  (Balster Einheitserdewerk)
90
Balster Einheitserdewerk ro 15-4513
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Ro 15 4513, supplied by Balster Einheitserdewerk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ro 15-4513/product/Balster Einheitserdewerk
Average 90 stars, based on 1 article reviews
ro 15-4513 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
zv-methyl-3h]ro 15-1788  (New England Nuclear Corporation)
90
New England Nuclear Corporation zv-methyl-3h]ro 15-1788
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Zv Methyl 3h]Ro 15 1788, supplied by New England Nuclear Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/zv-methyl-3h]ro 15-1788/product/New England Nuclear Corporation
Average 90 stars, based on 1 article reviews
zv-methyl-3h]ro 15-1788 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
flumazenil (ro15-1788; ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4 h -benzo[ f ]imidazo[1,5- a ][1,4]diazepine-3-carboxylate)  (Biotrend Chemicals)
90
Biotrend Chemicals flumazenil (ro15-1788; ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4 h -benzo[ f ]imidazo[1,5- a ][1,4]diazepine-3-carboxylate)
Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of <t>flumazenil</t> (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .
Flumazenil (Ro15 1788; Ethyl 8 Fluoro 5 Methyl 6 Oxo 5,6 Dihydro 4 H Benzo[ F ]Imidazo[1,5 A ][1,4]Diazepine 3 Carboxylate), supplied by Biotrend Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flumazenil (ro15-1788; ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4 h -benzo[ f ]imidazo[1,5- a ][1,4]diazepine-3-carboxylate)/product/Biotrend Chemicals
Average 90 stars, based on 1 article reviews
flumazenil (ro15-1788; ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4 h -benzo[ f ]imidazo[1,5- a ][1,4]diazepine-3-carboxylate) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of flumazenil (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Neutralization of acyl-CoA-binding protein attenuates glucocorticoid-mediated suppression of cancer immunosurveillance

doi: 10.1073/pnas.2518983123

Figure Lengend Snippet: Modulation of antigen cross-presentation and Tsc22d3/TSC22D3 expression by ACBP/DBI neutralization in dendritic cells under glucocorticoid treatment. ( A ) The heatmap depicts the gene expression levels of mouse GM-CSF BMDCs isolated after 18 h of different treatments as indicated: vehicle; corticosterone (CORT, 1 μM); αDBI antibody (2.5 μg/mL) or its isotype (2.5 μg/mL). The computed P -values are presented in squares with different colors. Statistical analyses were performed by one-way ANOVA with Tukey correction. Tsc22d3 mRNA levels were measured by RT-qPCR in mouse BMDCs treated with corticosterone (CORT, 1 µM) in the presence or absence of flumazenil (1 µM) or bicuculline (10 µM) ( B ), or in Gabrg2 wild-type ( Gabrg2 WT/WT ) or Gabrg2 knock-in ( Gabrg2 F77I/F77I ) backgrounds ( C ). Tsc22d3/TSC22D3 expression was further assessed in mouse splenocytes ( D ) exposed to corticosterone (CORT, 1 µM), in human peripheral blood mononuclear cells (PBMCs; E ) and human monocyte-derived dendritic cells (moDCs; F ) exposed to hydrocortisone (HCS, 0.5 µM), each treated in the presence or absence of an ACBP/DBI-neutralizing antibody (αDBI; 2,5 µg/mL), as indicated. For panels ( B – F ), gene expression was quantified by RT-qPCR, normalized to housekeeping gene expression, and expressed as fold change relative to the corresponding untreated control condition within each experiment. Data are presented as columns with individual data points overlaid and shown as mean ± SEM. Statistical analyses were performed using ANOVA with correction for multiple comparisons; exact P values are indicated above the corresponding comparisons. ( G – I ) Upon CORT treatment, the efficacy of oxaliplatin (OXA; 5 mg/kg; i.p.) combined with either αPD1 antibody or its isotype control (200 µg/mouse; i.p.) and αDBI antibody or its isotype control (5 mg/kg) was assessed against MCA205 tumors in LysM-creX Tsc22d3 +/+ (n = 4 to 13 mice per group) ( H ) or LysM-creX Tsc22d3 −/− (n = 5 to 12 mice per group) ( I ) 8 to 10-wk-old male mice. Statistical analysis was performed using mixed linear model of tumor growth ( https://kroemerlab.shinyapps.io/TumGrowth/ ). Computed P -values are reported in panels H and I .

Article Snippet: Flumazenil (TopScience, #78755-81-4), bicuculline (MedChemExpress, #HY-N0219), corticosterone (Sigma-Aldrich, #27840), and hydrocortisone (MedChemExpress, Cat# HY-N0583) were dissolved in DMSO to prepare stock solutions and diluted in culture medium to the indicated working concentrations immediately before use.

Techniques: Expressing, Neutralization, Gene Expression, Isolation, Quantitative RT-PCR, Knock-In, Derivative Assay, Control